Agio Capital is happy and proud to have successfully supported another deal: the acquisition of Apitope by Worg Pharmaceuticals.
Analysis: China's biotech sector comes of age with big licensing deals, global ambitions. We're the living proof of the growing impact of the Chinese life sciences and biotech market!
Many events are happening the coming weeks, with the next Biowin – AGIO workshop being one of them. This online workshop is taking place September 30, from 10-12AM CET.
On October 5th, we're honored to co-organize with Industrial Technology Research Institute (ITRI)( 工業技術研究院 , 工研院 ) a CNS symposium in Taipei, Taiwan.
mRNA technology is getting more and more attention, because of its use in COVID-19 vaccines, yet its use is more applicable than for COVID-19 only. Our client eTheRNA is one of the pioneering companies using this technology.
Expanding Complix’s revolutionary Cell-Penetrating Alphabody platform beyond oncology & autoimmune diseases
We are featured in a webinar hosted by our partner BioIndustry Association UK.
Every year, Mediaplanet publishes a Life Sciences editorial with interesting case studies, interviews and news happening in the life sciences sector. This year, AGIO is featured in there together with Complix, the company we recently helped signing a deal with the Chinese NASDAQ listed company I-Mab.
2020 was the year when the world noticed they had to watch out for China. For the first time, China received more foreign investments than the US. That is just the beginning of the increasing power China has been exercising.
Agio Capital & Business Solutions and Agio Law assisted the Belgian telecom & utilities contractor OMV Natie in a transaction with Constructel/Visabeira.
AGIO Capital & Business Solutions supported Complix in signing a global drug discovery and development agreement against two immuno-oncology intracellular targets, with Nasdaq listed I-Mab.
Supporting the investment and a 50:50 joint collaboration to commercialize MED3000 in Greater China & South-East Asia
On February 15, 2021 Henk Joos, Roel Van Ranst and Philippe Van den Broecke were interviewed by FOKUS Business Guide about the relationship between AGIO Capital & Business Solutions and AGIO Law, and the position of Asia in the global business world.
Our interview in the newsletter of BioVox (december 2020)
China Grand Pharmaceutical announced the successful set up of AuroRNA Biotech, a joint venture between eTheRNA immunotherapies and China Grand Pharmaceutical.
Agio Capital & Business Solutions supported KLV in reinforcing their team and shareholding
Octimet Oncology announces licensing deal with Shanghai Allist Pharmaceuticals for Greater China
Proud to have supported 2 of the top 10 companies in capital raising
Supporting the € 24M financing round and contribution of Chinese capital
Supporting the € 34M Series B round of eTheRNA immunotherapies and the outline of a new strategic partnership
Agoria article by one of our Partners highlights opportunities in China during corona times
Co-organization of Belgium Road Show Track at the China healthcare summit 2019
From 0 to the nr. 2 largest healthcare market globally, and here to stay
Our interview in BioVox
Agio Capital & Business Solutions will lead the China Life Sciences workshop at knowledge for growth 2019, Europe's finest life sciences conference.
Supporting the € 14.6M raise of convertible bonds of Promethera® Biosciences
Our Healthcare Director Henk Joos joined the expert panel discussion